lvisa
@oncolvisa
Followers
435
Following
4K
Media
97
Statuses
6K
Oncologist focus on GI tumors. Biliary-pancreatic& gastroesophaguesl tumors in @hospitaldelmar @HMar_research.
Joined July 2011
RT @DraMartinezLago: 📌 KEYNOTE-585 Final Analysis..🧑⚕️ Resectable GC/GEJ (~1000 pts).💊 Pembro+CT vs placebo+CT.Mai….
0
19
0
RT @DraMartinezLago: 📄 Clinical significance of ecDNA in FGFR2-amplified gastric cancer.🔗 🔬 ecDNA can drive FGFR2 a….
0
4
0
RT @KoheiShitara: We report a case of gastric cancer with ecDNA carrying FGFR2 amplification in @JCOPO_ASCO @ASCO—mechanism of resistance w….
0
14
0
RT @KoheiShitara: Final OS analysis of KN585 published in @JCO_ASCO @ASCO. OS HR has been changed from 0.90 at primary @TheLancetOncol to 0….
0
24
0
RT @Popeta11: Paraules catalanes boniques:. Xiuxiuejar.Batec.Atzavara.Clam.Aixopluc.Moixaina.Caliu.Tendresa.Lluny.Fita.Rampoina.Xiscle.Papa….
0
690
0
RT @Erman_Akkus: Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric ad….
esmogastro.org
Malnutrition, prevalent in locally advanced oesophagogastric adenocarcinoma (LA-OGA), has an undetermined impact on survival. This study aimed to elucidate the association between survival and...
0
10
0
RT @Erman_Akkus: ☢️Conversion therapy for unresectable pancreatic cancer.CONKO-007 @JCO_ASCO . ➡️3mo induction ChT (84% Folfirinox).➡️Then….
0
22
0
RT @Erman_Akkus: 🟠Perioperativd toripalimab plus CapeOX for MSI-H GC/EGJC .NICE @eClinicalMed . ➡️cT3–4aNxM0 or cT2N + M0.➡️4x-Surgery-4x….
0
13
0
RT @MarioBalsaMD: 🚨 Real-world ICI efficacy in MSI/dMMR BTC (n=48, 🇫🇷 cohort). 🎯 mOS 40.9m | mPFS: 11.2m | ORR 36%….
ejcancer.com
Immune checkpoint inhibitors (ICIs) significantly improve survival in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI) tumors. In 2022, ICIs were approved as...
0
13
0
RT @Erman_Akkus: 📋❓Should we withhold targeted cancer therapies or immunotherapy during RT?. ✅@myESMO and @ESTRO_RT framework. 👉 https://t.c….
0
40
0
RT @pashtoonkasi: 🆕🗞️Hot off the press! @NatureMedicine. #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽. More to come w….
0
100
0
RT @ArndtVogel: Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.@ESMO_Open . https://t.co….
0
3
0
RT @MainatJM: Un dilema clàssic. Què prefereixes?. - Un milió d'euros ara mateix?. - O un cèntim que es va doblant cada dia (0.01€, 0,02€,….
0
44
0
RT @KoheiShitara: Representative case of zolbetuximab-induced gastritis that improved despite continued treatment. A case series with addit….
0
19
0
RT @skopetz: Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activ….
0
12
0
RT @Erman_Akkus: Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials - Cancer Treat….
cancertreatmentreviews.com
Perioperative chemotherapy is now widely recognized as a global approach for patients with resectable esophageal, gastroesophageal junction (GEJ), and gastric cancers [1,2]. In parallel, the promis...
0
6
0
RT @jsoriamd: Cancer cachexia = an underdiagnosed, lethal syndrome. · Affects up to 80% in pancreatic CA, 40% in lung. · It’s not just weig….
0
53
0
RT @OscarTahuahua: Excellent review in @NatRevClinOncol📣🌟. An integrated algorithm for Cancer of Unknown Primary diagnosis & treatment comb….
0
124
0
RT @Erman_Akkus: 🔬Are biomarkers predictive for neoadjuvant FLOT in gastric cancer ❓.@JCOPO_ASCO . ❌HER2, PD-L1, and CLDN18.2 ➡️ not linked….
0
17
0
RT @ArndtVogel: 🔥hot off the press.👉2 great papers supporting combinations of immune & RAS-directed therapies in #PDAC.@Cancer_Cell .👇https….
0
25
0